Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer

This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2 -amplified biliary tract cancer with a HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2025-11-20
DOI
https://doi.org/10.1001/jamaoncol.2025.4736
Citations
1
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
2.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer

Yixing Jiang, Phillip M. Garfin, Madappa N. Kundranda, Laëtitia Dahan et al.
1 citations
JAMA Oncology
Cholangiocarcinoma and Gallbladder Cancer Studies
2.01
article

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer

Yixing Jiang, Phillip M. Garfin, Madappa N. Kundranda, Laëtitia Dahan, Ari David Baron, Marine Jary, Filippo de Braud, Mohamedtaki Abdulaziz Tejani, Roberto Pazo-Cid, Muhammad Shaalan Beg, Elisabetta Fenocchio, J. Adeva Alfonso, Hui‐Chuan Sun, Myung Ah Lee, Aaron J. Scott, Lequn Bao, Roopinder Gillmore, Daneng Li, David Tougeron, Andrés Jesús Muñoz Martín, Jieer Ying, Laura Layos, Shubham Pant, Benjamin Tan, Omkar Marathe, Sara Lonardi, Qiang Yan, Massimo Aglietta, Antonio Cubillo Gracián, Do‐Youn Oh, Jung Hun Kang, Emerson Y. Chen, Harpreet Wasan, Lorenza Rimassa, Eric X. Chen, Sebastián Mondaca, Jean‐Philippe Metges, Ghassan K. Abou‐Alfa, Teresa Macarulla, John A. Bridgewater, Michel Ducreux, Olumide Gbolohon, Haitao Zhao, Jin Won Kim, Jia Fan, Ying Cheng, Yi Zhao, Xiaotian Wu, Rosa Alonso, Yuanyuan Bao, Hye Jin Choi, Saeed Sadeghi, Paula Ribera Fernandez, Jonathon Gable, Joon Oh Park, Paula Carrasco Aguirre, Heung-Moon Chang, Feng Xie, Gentry George King, Milind Javle, James J. Harding, Tingbo Liang, Xiaoyu Yin
article en
1 citations

Abstract

This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2 -amplified biliary tract cancer with a HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.

JAMA OncologyVol. 12(1)
Ulsan College (KR), Hebron University (PS), Verizon (United States) (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Sun Yat-sen University (CN), Oregon Health & Science University (US), Yonsei University (KR), Cornell University (US), Fudan University (CN), Université Paris-Saclay (FR), Asan Medical Center (KR), Hammersmith Hospital (GB), Institut Gustave Roussy (FR), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), University of Ulsan (KR), London Cancer (GB), Zhejiang Cancer Hospital (CN), Jazz Pharmaceuticals (United States) (US), Beijing Enterprises (China) (CN), Zhongshan Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Centre Hospitalier Régional Universitaire de Brest (FR), Cancer Institute of Florida (US), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Chinese People's Liberation Army (CN), Hubei Cancer Hospital (CN), University College London (GB), Imperial College London (GB), Catholic University of Korea (KR)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Exelixis, Jazz Pharmaceuticals, Les Laboratories Pierre Fabre, BeiGene, Incyte, G1 Therapeutics, Seagen, Servier, Sirtex Medical, Genentech, Foundation Medicine, Daiichi Sankyo Europe
Openalex Percentile: Top 10%
Cholangiocarcinoma and Gallbladder Cancer Studies
2.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.